| Year |
Citation |
Score |
| 2020 |
Vidal-Vanaclocha F, Crende O, García de Durango C, Herreros-Pomares A, López-Doménech S, González Á, Ruiz-Casares E, Vilboux T, Caruso R, Duran H, Gil A, Ielpo B, Lapuente F, Quijano Y, Vicente E, ... ... Sotomayor EM, et al. Liver Prometastatic Reaction: Stimulating Factors and Responsive Cancer Phenotypes. Seminars in Cancer Biology. PMID 32805395 DOI: 10.1016/J.Semcancer.2020.08.001 |
0.314 |
|
| 2020 |
Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C, Manhas N, Simonyan H, Young CN, Popratiloff A, Chiappinelli KB, Fernandes R, Sotomayor EM, Villagra A. HDAC6 plays a non-canonical role in the regulation of anti-tumor immune responses, dissemination, and invasiveness of breast cancer. Cancer Research. PMID 32605998 DOI: 10.1158/0008-5472.Can-19-3738 |
0.346 |
|
| 2020 |
Beltrán BE, Villela L, Torres MA, Otero V, Fiad L, Peña C, Cabrera ME, León P, Idrobo H, Castro DA, Paredes S, Perdomo I, Abello V, Rojas C, Ramirez-Ibargüen A, ... ... Sotomayor EM, et al. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clinical Lymphoma, Myeloma & Leukemia. PMID 32513598 DOI: 10.1016/J.Clml.2020.04.016 |
0.362 |
|
| 2020 |
Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 1531. PMID 32169966 DOI: 10.1158/1078-0432.Ccr-20-0412 |
0.33 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, ... ... Sotomayor EM, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.4 |
|
| 2019 |
Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo JJ. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clinical Lymphoma, Myeloma & Leukemia. PMID 31320254 DOI: 10.1016/J.Clml.2019.06.005 |
0.357 |
|
| 2019 |
Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, Greipp PT, Elsawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. Journal of Hematology & Oncology. 12: 73. PMID 31288832 DOI: 10.1186/S13045-019-0761-2 |
0.409 |
|
| 2019 |
Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, ... ... Sotomayor EM, et al. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 35: 752-766.e9. PMID 31085176 DOI: 10.1016/J.Ccell.2019.04.005 |
0.341 |
|
| 2019 |
Kahl BS, Dreyling M, Gordon LI, Martin P, Quintanilla-Martinez L, Sotomayor EM. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. Leukemia & Lymphoma. 1-13. PMID 30696305 DOI: 10.1080/10428194.2019.1571205 |
0.375 |
|
| 2019 |
Cheng F, Yan D, Chen J, Keidar M, Sotomayor E. Cold Plasma with Immunomodulatory Properties Has Significant Anti-Lymphoma Activities in Vitro and In Vivo Blood. 134: 5307-5307. DOI: 10.1182/Blood-2019-131065 |
0.473 |
|
| 2019 |
Sharma V, Yue L, Horvat NP, Christodoulidou A, Akuffo AA, Beatty M, Murdun C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville L, ... ... Sotomayor E, et al. Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474. DOI: 10.1182/Blood-2019-127235 |
0.394 |
|
| 2019 |
Alsharif R, Nassereddine S, Akin E, Karcher D, Smith M, Sotomayor E, Dunleavy K. Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma Blood. 134: 5355-5355. DOI: 10.1182/Blood-2019-124081 |
0.34 |
|
| 2019 |
M LV, Ramirez-Ibarguen A, Beltrán BE, Otero V, Castro DA, Candelaria M, Pérez-Jacobo F, Montaño Figueroa E, Peña C, Paredes SR, Best C, Gómez-De León A, Gomez-Almaguer D, Ruiz-Arguelles GJ, Idrobo H, ... ... Sotomayor E, et al. Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival Blood. 134: 1613-1613. DOI: 10.1182/Blood-2019-123841 |
0.304 |
|
| 2019 |
Idrobo H, Beltrán BE, M LV, Torres Viera M, Otero V, Fiad L, Peña C, Castro DA, Huerta- Collado YM, Paredes SR, Perdomo I, León P, Rojas C, Abello V, Osuna Pérez M, ... ... Sotomayor E, et al. Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL) Blood. 134: 4047-4047. DOI: 10.1182/Blood-2019-123588 |
0.312 |
|
| 2019 |
Malpica Castillo LE, Peña C, Rojas C, León P, Beltrán BE, Castro DA, Huerta- Collado YM, Quinones M, Paredes SR, Idrobo H, Perdomo I, Abello V, Fiad L, Otero V, Torres Viera M, ... ... Sotomayor E, et al. Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL) Blood. 134: 4045-4045. DOI: 10.1182/Blood-2019-122976 |
0.343 |
|
| 2019 |
Beltrán B, Otero V, Peña C, Fiad L, Mahuad C, Perdomo I, Castro Uriol D, Torres Viera M, Rodriguez M, Chisesi T, Valvert F, Ignacio G, Chiattone C, Villela L, Idrobo H, ... ... Sotomayor E, et al. PRE-TREATMENT SERUM ALBUMIN LEVEL AS A MEANS OF IMPROVING PROGNOSTIC MODELS IN PERIPHERAL T-CELL LYMPHOMAS: A STUDY FROM THE LATIN AMERICAN GROUP OF LYMPHOMAS (GELL) Hematological Oncology. 37: 463-464. DOI: 10.1002/Hon.142_2631 |
0.369 |
|
| 2018 |
Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, Quayle SN, Jones SS, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances. 2: 3012-3024. PMID 30425065 DOI: 10.1182/Bloodadvances.2018020065 |
0.45 |
|
| 2018 |
Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, ... ... Sotomayor EM, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. The Journal of Clinical Investigation. PMID 30260324 DOI: 10.1172/Jci122533 |
0.371 |
|
| 2018 |
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. American Journal of Hematology. 93: 953-962. PMID 29984868 DOI: 10.1002/Ajh.25112 |
0.336 |
|
| 2018 |
Beltran BE, Castro D, De La Cruz-Vargas JA, Cotrina E, Gallo A, Sotomayor EM, Castillo JJ. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. British Journal of Haematology. PMID 29479670 DOI: 10.1111/Bjh.15141 |
0.399 |
|
| 2018 |
Beltrán BE, Paredes S, Cotrina E, Sotomayor EM, Castillo JJ. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leukemia Research. 67: 82-85. PMID 29477024 DOI: 10.1016/J.Leukres.2018.02.011 |
0.334 |
|
| 2018 |
Paredes S, Beltran BE, Sotomayor EM, Castillo JJ, Salas R. High RDW as a predictive and prognostic factor in patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy. Journal of Clinical Oncology. 36: e19547-e19547. DOI: 10.1200/Jco.2018.36.15_Suppl.E19547 |
0.343 |
|
| 2018 |
Nogues JC, Wang ZM, Chisholm SS, Smith M, Sotomayor E, Chiappinelli K. The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies Blood. 132: 5157-5157. DOI: 10.1182/Blood-2018-99-120281 |
0.373 |
|
| 2018 |
Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Nguyen T, Alsina M, Nishihori T, Baz R, Pinilla Ibarz J, Sotomayor E, Shain KH, Brayer JB. Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival Blood. 132: 3223-3223. DOI: 10.1182/Blood-2018-99-119119 |
0.461 |
|
| 2018 |
Ren Y, Bi C, Zhao X, Lwin T, Cheng W, Yuan J, Siqueira Silva A, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, ... ... Sotomayor E, et al. Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas Blood. 132: 2853-2853. DOI: 10.1182/Blood-2018-99-118004 |
0.415 |
|
| 2018 |
Beltrán BE, Castro DA, Vega J, Malaga JM, Postigo M, Gallo A, Sotomayor E, Castillo JJ. The Impact on Survival of EBV Positive Diffuse Large B- Cell Lymphoma, Not Otherwise Specified in Young Adults Blood. 132: 5407-5407. DOI: 10.1182/Blood-2018-99-117662 |
0.35 |
|
| 2018 |
Beltrán BE, Castro DA, Huerta- Collado YM, Malaga JM, Postigo M, Sotomayor E, Castillo JJ. Clinical Characteristics and Survival in Patients with EBV Positive Diffuse Large B- Cell Lymphoma, Not Otherwise Specified: Report of 60 Cases Blood. 132: 2986-2986. DOI: 10.1182/Blood-2018-99-117185 |
0.335 |
|
| 2018 |
Chen J, Cheng F, Wang M, Sahakian E, Powers JJ, Pinilla Ibarz J, Smith MR, Sotomayor E. Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment Blood. 132: 1105-1105. DOI: 10.1182/Blood-2018-99-117007 |
0.481 |
|
| 2018 |
Cheng F, Ren Y, Chen J, Wang Z, Li T, Dunleavy K, Lin J, Bradner J, Smith MR, Shah BD, Sotomayor E, Tao J. C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition Blood. 132: 777-777. DOI: 10.1182/Blood-2018-99-116865 |
0.429 |
|
| 2018 |
Zhao X, Jiang H, Wang M, Li T, Gao J, Lwin T, Ren Y, Sotomayor E, Shah BD, Tao J. Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL) Blood. 132: 2651-2651. DOI: 10.1182/Blood-2018-99-116756 |
0.39 |
|
| 2018 |
Beltrán BE, Otero V, Torres Viera M, Peña C, Rodriguez ML, Borelli G, Chisesi T, Valvert Gamboa F, Berrios A, Ignacio G, Chiattone CS, Paredes S, Castro DA, Cabrera ME, Gabus R, ... Sotomayor E, et al. The Neutrophil-to-Lymphocyte Ratio Is Prognostic in Patients with Diffuse Large B-Cell Lymphoma: A Study from the Latin American Group of Lymphomas (GELL) Blood. 132: 2987-2987. DOI: 10.1182/Blood-2018-99-113246 |
0.341 |
|
| 2018 |
Beltrán BE, Castro DA, Huerta- Collado YM, Sotomayor E, Castillo JJ. RDW Is a Prognostic Marker for Patients with Aggressive Peripheral T-Cell Lymphoma Blood. 132: 5364-5364. DOI: 10.1182/Blood-2018-99-113236 |
0.413 |
|
| 2018 |
Beltrán BE, Otero V, Torres Viera M, Peña C, Rodriguez ML, Borelli G, Chisesi T, Valvert Gamboa F, Berrios A, Ignacio G, Chiattone CS, Paredes S, Castro DA, Cabrera ME, Gabus R, ... Sotomayor E, et al. Validation of the Nccn-Ipi for Diffuse Large B-Cell Lymphoma in Latin American Patients: A Study from the Latin-American Group of Lymphomas (GELL) Blood. 132: 5395-5395. DOI: 10.1182/Blood-2018-99-113214 |
0.338 |
|
| 2018 |
Beltrán BE, Castro DA, Huerta- Collado YM, Sotomayor E, Castillo JJ. The NCCN-IPI Score Is Prognostic of Survival in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified Blood. 132: 5363-5363. DOI: 10.1182/Blood-2018-99-113187 |
0.345 |
|
| 2018 |
Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition Cancer Research. 78: 4967-4967. DOI: 10.1158/1538-7445.Am2018-4967 |
0.473 |
|
| 2018 |
Banik D, Hadley M, Palmer E, Gallub V, Sotomayor E, Kozikowski A, Villagra A. Abstract 48: Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy Cancer Research. 78: 48-48. DOI: 10.1158/1538-7445.Am2018-48 |
0.405 |
|
| 2017 |
Huang J, Wang L, Dahiya S, Beier UH, Han R, Samanta A, Bergman J, Sotomayor EM, Seto E, Kozikowski AP, Hancock WW. Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Scientific Reports. 7: 8626. PMID 28819166 DOI: 10.1038/S41598-017-09211-3 |
0.346 |
|
| 2017 |
Beltran BE, Quiñones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, Castillo JJ. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematological Oncology. PMID 28639256 DOI: 10.1002/Hon.2449 |
0.33 |
|
| 2017 |
Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, ... ... Sotomayor EM, et al. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology. PMID 28550123 DOI: 10.1189/Jlb.1A0415-176Rrr |
0.376 |
|
| 2017 |
Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, ... ... Sotomayor EM, et al. T-cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. PMID 28550044 DOI: 10.1182/Blood-2016-08-731505 |
0.467 |
|
| 2017 |
Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, ... ... Sotomayor E, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nature Communications. 8: 14920. PMID 28416797 DOI: 10.1038/Ncomms14920 |
0.385 |
|
| 2017 |
Sandoval-Sus J, Sotomayor EM, Shah BD. Mantle cell lymphoma: Contemporary diagnostic and treatment perspectives in the age of personalized medicine. Hematology/Oncology and Stem Cell Therapy. PMID 28404221 DOI: 10.1016/J.Hemonc.2017.02.003 |
0.352 |
|
| 2017 |
Kahl BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, Sotomayor EM. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop. Leukemia & Lymphoma. 1-12. PMID 28140709 DOI: 10.1080/10428194.2017.1283036 |
0.377 |
|
| 2017 |
Khushalani NI, Markowitz J, Eroglu Z, Giuroiu I, Ladanova V, Reiersen P, Rich J, Thapa R, Schell MJ, Sotomayor EM, Weber JS. A phase I trial of panobinostat with ipilimumab in advanced melanoma. Journal of Clinical Oncology. 35: 9547-9547. DOI: 10.1200/Jco.2017.35.15_Suppl.9547 |
0.323 |
|
| 2017 |
Distler A, Brayer JB, Meads M, Sahakian E, Powers JJ, Alsina M, Nishihori T, Baz RC, Pinilla-Ibarz J, Sotomayor EM, Shain KH. HDAC11 as a candidate therapeutic target in multiple myeloma. Journal of Clinical Oncology. 35: 8029-8029. DOI: 10.1182/Blood.V130.Suppl_1.1800.1800 |
0.431 |
|
| 2017 |
Hadley M, Shen S, Banik D, Kim J, Nair J, Knox T, Gallub V, Kirkland S, Chiappinelli KB, Sotomayor E, Kozikowski A, Villagra A. Abstract LB-294:In vivoevaluation of Ames negative HDAC6 inhibitor in melanoma model Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-294 |
0.387 |
|
| 2017 |
Cheng F, Andressa S, Chen J, Villagra A, Woods D, Weber J, Quayle S, Simon J, Sotomayor E. Abstract 4976: Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant antimelanoma activity in vitro and in vivo Cancer Research. 77: 4976-4976. DOI: 10.1158/1538-7445.Am2017-4976 |
0.401 |
|
| 2017 |
Banik D, Hadley M, Kim J, Knox T, Nair J, Kozikowski A, Shen S, Vyas C, Donohue A, Sotomayor E, Villagra A. Abstract 4854: Evaluating HDAC6 as a causal factor in metastatic breast cancer to develop immunotherapy Cancer Research. 77: 4854-4854. DOI: 10.1158/1538-7445.Am2017-4854 |
0.393 |
|
| 2017 |
Knox T, Sahakian E, Nair J, Kim J, Banik D, Hadley M, Powers J, Cheng F, Shen S, Pinilla J, Weber J, Kozikowski A, Sotomayor E, Villagra A. Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6 Cancer Research. 77: 4055-4055. DOI: 10.1158/1538-7445.Am2017-4055 |
0.345 |
|
| 2016 |
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 91: 529-37. PMID 27093913 DOI: 10.1002/Ajh.24370 |
0.345 |
|
| 2016 |
Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KS, Montecino M, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, ... ... Sotomayor EM, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Molecular Oncology. PMID 26775640 DOI: 10.1016/J.Molonc.2015.12.012 |
0.369 |
|
| 2016 |
Cheng F, Laino AS, Wang H, Chen J, Villagra A, Woods DM, Weber JS, Quayle S, Jones SS, Sotomayor EM. In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties. Journal of Clinical Oncology. 34: e21075-e21075. DOI: 10.1200/Jco.2016.34.15_Suppl.E21075 |
0.35 |
|
| 2016 |
Talati C, Sandoval-Sus JD, Dalia S, Shah BD, Bello CM, Chervenick PA, Ayala E, Locke FL, Kharfan-Dabaja MA, Sotomayor EM, Sokol L, Chavez JC. The prognostic impact of serum albumin in double hit/double expressing aggressive B cell lymphomas: A pilot study evaluating SAAB scoring system. Journal of Clinical Oncology. 34: e19044-e19044. DOI: 10.1200/Jco.2016.34.15_Suppl.E19044 |
0.37 |
|
| 2016 |
Laino AS, Woods DM, Sarnaik A, Quayle3 S, Jones3 SS, Sotomayor EM, Weber JS. Selective histone deacetylase inhibition augments melanoma immunotherapy. Journal of Clinical Oncology. 34: e14521-e14521. DOI: 10.1200/Jco.2016.34.15_Suppl.E14521 |
0.347 |
|
| 2016 |
Sandoval-Sus JD, Dalia S, Talati C, Shah BD, Bello CM, Lancet JE, Chervenick PA, Locke FL, Kharfan-Dabaja M, Sotomayor EM, Sokol L, Chavez JC, Pinilla-Ibarz J. Impact of IgVH mutational status in patients with chronic lymphocytic leukemia with isolated good and intermidiate risk genetic aberrations. Journal of Clinical Oncology. 34: 7534-7534. DOI: 10.1200/Jco.2016.34.15_Suppl.7534 |
0.331 |
|
| 2016 |
Chen J, Cheng F, Woods DM, Seto E, Villagra A, Sotomayor EM. Histone Deacetylase 11 (HDAC11) Interaction with Ikaros Represent a Novel Mechanism of Regulation of Essential Transcriptional Factors in CD4+ T Cells Blood. 128: 864-864. DOI: 10.1182/Blood.V128.22.864.864 |
0.434 |
|
| 2016 |
Beltran BE, Castro D, Motta R, Paredes S, Malaga JM, Miranda RN, Sotomayor EM, Castillo JJ. The Neutrophil-to-Lymphocyte Ratio Is Prognostic in Patients with Early Stage Peripheral T-Cell Lymphoma Blood. 128: 5346-5346. DOI: 10.1182/Blood.V128.22.5346.5346 |
0.358 |
|
| 2016 |
Talati C, Kuykendall A, Kaplan J, Sandoval-Sus JD, Dalia S, Shah BD, Bello CM, Khimani F, Chervenick PA, Ayala E, Locke FL, Kharfan-Dabaja MA, Sotomayor EM, Sokol L, Chavez JC. Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score Blood. 128: 1870-1870. DOI: 10.1182/Blood.V128.22.1870.1870 |
0.334 |
|
| 2016 |
Laino AS, Woods DM, Sarnaik A, Weber J, Sotomayor EM. Abstract A074: Selective Inhibition of HDAC6 augments T-cell central memory and enhances anti-tumor functions: Implications in TIL therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A074 |
0.459 |
|
| 2016 |
Woods DM, Sodre AL, Woan K, Villagra A, Sarnaik A, Weber J, Sotomayor EM. Abstract A066: Histone deacetylase 11 is an epigenetic regulator of T-cell pro-inflammatory function and novel target for enhancing T-cell anti-tumor activity Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A066 |
0.473 |
|
| 2016 |
Knox T, Lienlaf M, Perez P, Pabon M, Lee C, Cheng F, Sahakian E, Powers J, Deng S, Keiran S, Kozikowski A, Pinilla J, Sarnaik A, Seto E, Weber J, ... Sotomayor E, et al. Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways Cancer Research. 76: 2331-2331. DOI: 10.1158/1538-7445.Am2016-2331 |
0.349 |
|
| 2016 |
Sandoval-Sus J, Chavez J, Parra P, Bello C, Chervenick P, Lancet J, Sokol L, Sotomayor E, Locke F, Kharfan-Dabaja M, Shah B, Ayala E. Allogeneic Hematopoietic Stem Cell Transplantation in Mantle Cell Lymphoma: a Single Institution Experience Clinical Lymphoma Myeloma and Leukemia. 16: S115-S116. DOI: 10.1016/J.Clml.2016.07.167 |
0.315 |
|
| 2016 |
Talati C, Kuykendall A, Kaplan J, Sandoval-Sus J, Dalia S, Shah B, Bello C, Chervenick P, Ayala E, Locke F, Kharfan-Dabaja M, Sotomayor E, Sokol L, Chavez J. Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas Clinical Lymphoma Myeloma and Leukemia. 16: S99. DOI: 10.1016/J.Clml.2016.07.142 |
0.34 |
|
| 2015 |
Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research. PMID 26297712 DOI: 10.1158/2326-6066.Cir-15-0077-T |
0.355 |
|
| 2015 |
Horna P, Kurant D, Sokol L, Sotomayor EM, Moscinski L, Glass LF. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides. American Journal of Clinical Pathology. 143: 785-96. PMID 25972320 DOI: 10.1309/Ajcpwe2Hbfcgdids |
0.391 |
|
| 2015 |
Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KS, Bergman J, ... ... Sotomayor EM, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology. PMID 25957812 DOI: 10.1016/J.Molonc.2015.04.002 |
0.463 |
|
| 2015 |
Kahl BS, Gordon LI, Dreyling M, Gascoyne RD, Sotomayor EM. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma. 56: 2505-11. PMID 25944379 DOI: 10.3109/10428194.2015.1045903 |
0.392 |
|
| 2015 |
Beltran BE, Aguilar C, Quiñones P, Morales D, Chavez JC, Sotomayor EM, Castillo JJ. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leukemia & Lymphoma. 1-5. PMID 25926063 DOI: 10.3109/10428194.2015.1045897 |
0.352 |
|
| 2015 |
Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget. 6: 9488-501. PMID 25839159 DOI: 10.18632/Oncotarget.3378 |
0.365 |
|
| 2015 |
Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology. 63: 579-85. PMID 25155994 DOI: 10.1016/J.Molimm.2014.08.002 |
0.412 |
|
| 2015 |
Wang H, Cheng F, Cheng J, Villagra A, Tao J, Bradner JE, Sotomayor EM. JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1 Blood. 126: 822-822. DOI: 10.1182/Blood.V126.23.822.822 |
0.523 |
|
| 2015 |
Beltran BE, Malaga JM, Chavez JC, Sotomayor EM, Castillo JJ. The Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma Blood. 126: 5047-5047. DOI: 10.1182/Blood.V126.23.5047.5047 |
0.356 |
|
| 2015 |
Sandoval-Sus JD, Chavez JC, Dalia S, Bello CM, Shah BD, Ho VQ, Nodzon L, Kharfan-Dabaja MA, Sotomayor EM, Sokol L, Pinilla-Ibarz J. Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience Blood. 126: 2945-2945. DOI: 10.1182/Blood.V126.23.2945.2945 |
0.355 |
|
| 2015 |
Laino AS, Woods DM, Celis E, Weber J, Sotomayor E. Abstract PR09: Targeting histone deacetylase 6 in T-cells to improve melanoma immunotherapy Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Pr09 |
0.5 |
|
| 2015 |
Woods DM, Sodre AL, Sarnaik A, Sotomayor EM, Weber J. Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade Cancer Research. 75: 257-257. DOI: 10.1158/1538-7445.Am2015-257 |
0.308 |
|
| 2015 |
Laino AS, Woods DM, Sarnaik A, Celis E, Weber J, Sotomayor EM. Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy Cancer Research. 75: 1338-1338. DOI: 10.1158/1538-7445.Am2015-1338 |
0.458 |
|
| 2015 |
Brayer J, Sahakian E, Nguyen D, Powers J, Meads M, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor E, Shain K. Histone deacetylase 11 (HDAC11) is critical for plasma cell development and multiple myeloma survival Clinical Lymphoma Myeloma and Leukemia. 15: e222-e223. DOI: 10.1016/J.Clml.2015.07.478 |
0.335 |
|
| 2015 |
Mathew B, Dalia S, Hall J, Shah B, Bello C, Sokol L, Sotomayor E, Chavez J. Analysis of Prognostic Factors in Patients with HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas Clinical Lymphoma Myeloma and Leukemia. 15: S230. DOI: 10.1016/J.Clml.2015.04.113 |
0.337 |
|
| 2014 |
Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, ... ... Sotomayor EM, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. Journal of Immunology (Baltimore, Md. : 1950). 193: 2850-62. PMID 25108026 DOI: 10.4049/Jimmunol.1302778 |
0.46 |
|
| 2014 |
Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Molecular Immunology. 60: 44-53. PMID 24747960 DOI: 10.1016/J.Molimm.2014.02.019 |
0.424 |
|
| 2014 |
Kizuka Y, Kitazume S, Okahara K, Villagra A, Sotomayor EM, Taniguchi N. Epigenetic regulation of a brain-specific glycosyltransferase N-acetylglucosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. The Journal of Biological Chemistry. 289: 11253-61. PMID 24619417 DOI: 10.1074/Jbc.M114.554311 |
0.307 |
|
| 2014 |
Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Annals of Hematology. 93: 1305-12. PMID 24590536 DOI: 10.1007/S00277-014-2031-2 |
0.35 |
|
| 2014 |
Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. International Journal of Hematology. 99: 450-6. PMID 24584873 DOI: 10.1007/S12185-014-1540-Z |
0.352 |
|
| 2014 |
Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. Journal of Clinical Pathology. 67: 431-6. PMID 24319102 DOI: 10.1136/Jclinpath-2013-201748 |
0.384 |
|
| 2014 |
Knox T, Lienlaf M, Perez-Villarroel P, Lee C, Sahakian E, Powers JJ, Cheng F, Canales J, Marante D, Seto E, Sotomayor EM, Villagra A, Horna P. Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition Blood. 124: 5423-5423. DOI: 10.1182/Blood.V124.21.5423.5423 |
0.45 |
|
| 2014 |
Beltran BE, Chavez JC, Sotomayor EM, Castillo JJ. Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse Large B-Cell Lymphoma Blood. 124: 5408-5408. DOI: 10.1182/Blood.V124.21.5408.5408 |
0.362 |
|
| 2014 |
Cheng F, Xia B, Sahakian E, Lwin T, Wang H, Xing L, Shah BD, PerezVillarroel P, LienlafMoreno M, Zhang Y, Quayle SN, Jones SS, Pinilla-Ibarz J, Villagra A, Sotomayor EM, et al. Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 124: 5397-5397. DOI: 10.1182/Blood.V124.21.5397.5397 |
0.442 |
|
| 2014 |
Brayer JB, Sahakian E, Powers J, Meads MB, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor EM, Shain KH. A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma Blood. 124: 4715-4715. DOI: 10.1182/Blood.V124.21.4715.4715 |
0.438 |
|
| 2014 |
Griffin PT, Chavez JC, Bello CM, Sokol L, Chervenick PA, Ayala E, Tao J, Sotomayor EM, Shah BD. Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis Blood. 124: 4424-4424. DOI: 10.1182/Blood.V124.21.4424.4424 |
0.342 |
|
| 2014 |
Powers JJ, Maharaj KK, Sahakian E, Xing L, PerezVillarroel P, Knox T, Quayle S, Jones SS, Villagra A, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL) Blood. 124: 3311-3311. DOI: 10.1182/Blood.V124.21.3311.3311 |
0.457 |
|
| 2014 |
Shah BD, Tao J, Chervenick PA, Riches ML, Pinilla-Ibarz J, Moscinski LC, Antonia S, Sotomayor EM, Dessureault S. Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL) Blood. 124: 3083-3083. DOI: 10.1182/Blood.V124.21.3083.3083 |
0.348 |
|
| 2014 |
Griffin PT, Dalia S, Shah BD, Sokol L, Bello CM, Chervenick PA, Sotomayor EM, Chavez JC. Multivariate Survival Analysis of Transformed Lymphoma in the Chemoimmunotherapy Era: Impact of the NCCN International Prognostic Index Blood. 124: 2981-2981. DOI: 10.1182/Blood.V124.21.2981.2981 |
0.305 |
|
| 2014 |
Chen J, Sahakian E, Powers JJ, LienlafMoreno M, Xing L, Deng S, Distler A, Cheng F, Villagra A, Horna P, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition Blood. 124: 225-225. DOI: 10.1182/Blood.V124.21.225.225 |
0.398 |
|
| 2014 |
Beltran BE, Castro D, Chavez JC, Sotomayor EM, Castillo JJ. The Prognostic Value of the Neutrophil to Lymphocyte Ratio in 209 Patients with Peripheral T-Cell Lymphoma Blood. 124: 1675-1675. DOI: 10.1182/Blood.V124.21.1675.1675 |
0.398 |
|
| 2014 |
Woods DM, Sodre AL, Brayer JB, Sotomayor EM. Abstract 643: The histone deacetylase inhibitor Quisinostat augments the anti-tumor reponses of T-cells: Implications in adoptive cell therapy Cancer Research. 74: 643-643. DOI: 10.1158/1538-7445.Am2014-643 |
0.497 |
|
| 2014 |
Sahakian E, Brayer J, Powers J, Meads M, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor E, Shain K. Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma Cancer Research. 74: 5537-5537. DOI: 10.1158/1538-7445.Am2014-5537 |
0.45 |
|
| 2014 |
Woods DM, Sodre AL, Sahakian E, Powers J, Lienlaf-Moreno M, Perez-Villarroel P, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy Cancer Research. 74: 4090-4090. DOI: 10.1158/1538-7445.Am2014-4090 |
0.421 |
|
| 2014 |
Lienlaf M, Perez-Villarroel P, Lee C, Cheng F, Canales J, Knox T, Marante D, Sarnaik A, Horna P, Seto E-, Smalley K, Weber JS, Sotomayor EM, Villagra A. Abstract 4089: Histone deacetylase 6 (HDAC6) as a regulator of PD-L1 expression through STAT3 modulation in melanoma Cancer Research. 74: 4089-4089. DOI: 10.1158/1538-7445.Am2014-4089 |
0.387 |
|
| 2014 |
Perez-Villarroel P, Lienlaf M, Lee C, Cheng F, Woods D, Barrios K, Woan K, Canales J, Knox T, Marante D, Wang H, Horna P, Smalley K, Celis E, Seto E, ... ... Sotomayor EM, et al. Abstract 4086: Histone deacetylase 6 (HDAC6) as a new target modulating the proliferation and immune-related pathways in melanoma Cancer Research. 74: 4086-4086. DOI: 10.1158/1538-7445.Am2014-4086 |
0.462 |
|
| 2014 |
Laino AS, Woods DM, Cheng F, Wang H, Sotomayor EM. Abstract 2564: Histone deacetylase 6 is a novel target for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination Cancer Research. 74: 2564-2564. DOI: 10.1158/1538-7445.Am2014-2564 |
0.467 |
|
| 2014 |
Woods DM, Laino A, Villagra A, Sotomayor EM. Molecular pathways in antigen-presenting cells involved in the induction of antigen-specific T-cell tolerance Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 411-433. DOI: 10.1007/978-1-4899-8056-4_15 |
0.31 |
|
| 2013 |
Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. The Journal of Clinical Investigation. 123: 4612-26. PMID 24216476 DOI: 10.1172/Jci64210 |
0.415 |
|
| 2013 |
Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Research. 23: 341-8. PMID 23963286 DOI: 10.1097/Cmr.0B013E328364C0Ed |
0.449 |
|
| 2013 |
Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 27: 2341-50. PMID 23538750 DOI: 10.1038/Leu.2013.94 |
0.326 |
|
| 2013 |
Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology. 14: 211-20. PMID 23354483 DOI: 10.1038/Ni.2526 |
0.388 |
|
| 2013 |
Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leukemia & Lymphoma. 54: 205-8. PMID 22694793 DOI: 10.3109/10428194.2012.697561 |
0.347 |
|
| 2013 |
Dalia S, Brayer JB, Chavez JC, Bello CM, Shah BD, Horna P, Zhang H, Sokol L, Sotomayor EM, Pinilla-Ibarz J. Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia Blood. 122: 5290-5290. DOI: 10.1182/Blood.V122.21.5290.5290 |
0.375 |
|
| 2013 |
Dalia S, Chavez JC, Bello CM, Chervenick PA, Sokol L, Tao J, Sotomayor EM, Shah BD. Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma Blood. 122: 5057-5057. DOI: 10.1182/Blood.V122.21.5057.5057 |
0.326 |
|
| 2013 |
Chen J, Powers J, Rock-Klotz J, Deng S, Distler A, Cheng F, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β Blood. 122: 4887-4887. DOI: 10.1182/Blood.V122.21.4887.4887 |
0.372 |
|
| 2013 |
Christina T, Dalia S, Bello CM, Sokol L, Sotomayor EM, Shah BD, Chavez JC. The Revised International Prognostic Index (R-IPI) Score Is Predictive Of Survival In Aggressive Transformed Lymphomas (TL) From Low Grade Non-Hodgkin Lymphomas In The Chemoimmunotherapy Era Blood. 122: 4275-4275. DOI: 10.1182/Blood.V122.21.4275.4275 |
0.33 |
|
| 2013 |
Dalia S, Chavez JC, Bello CM, Chervenick PA, Little BJ, Al Ali NH, Sokol L, Sotomayor EM, Lee J, Fisher K, Thompson Z, Choi B, Shah BD. A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI) Blood. 122: 4267-4267. DOI: 10.1182/Blood.V122.21.4267.4267 |
0.321 |
|
| 2013 |
Tao J, Shah BD, Zhang X, Rastogi P, Tao J, Lancet JE, Nieder M, Lin H, Sotomayor EM, Moscinski L, Zhang L. Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL) Blood. 122: 3875-3875. DOI: 10.1182/Blood.V122.21.3875.3875 |
0.329 |
|
| 2013 |
Sahakian E, Powers J, Chen J, Distler A, Rock-Klotz J, Deng S, Wei S, Sotomayor EM, Pinilla-Ibarz J, Horna P. A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis Blood. 122: 2267-2267. DOI: 10.1182/Blood.V122.21.2267.2267 |
0.442 |
|
| 2013 |
Sahakian E, Brayer JB, Powers J, Meads M, Distler A, Deng S, Alsina M, Nishihori T, Baz R, Pinilla-Ibarz J, Sotomayor EM, Shain K. A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival Blood. 122: 1907-1907. DOI: 10.1182/Blood.V122.21.1907.1907 |
0.42 |
|
| 2013 |
Wu H, Bui M, Shao H, Sokol L, Sotomayor EM, Bulkeley W, Zhang L. Prognostic Significance Of Soft Tissue Involvement and International Prognostic Index In Primary Bone Lymphoma– A Single Institutional Experience Blood. 122: 1781-1781. DOI: 10.1182/Blood.V122.21.1781.1781 |
0.311 |
|
| 2013 |
Little BJ, Chavez JC, Bello CM, Chervenick P, Sokol L, Sotomayor EM, Shah BD. A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma Blood. 122: 1702-1702. DOI: 10.1182/Blood.V122.21.1702.1702 |
0.326 |
|
| 2013 |
Laino AS, Woods DM, Cheng F, Wang H, Sotomayor EM. Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy Blood. 122: 1050-1050. DOI: 10.1182/Blood.V122.21.1050.1050 |
0.481 |
|
| 2013 |
Lienlaf M, Perez-Villarroel P, Cheng F, Lee CK, Canales J, Knox T, Marante D, Yoder SJ, Woan KV, Pinilla-Ibarz J, Seto E, Sotomayor EM, Villagra A. Role Of Histone Deacetylase 6 (HDAC6) In The Modulation Of STAT Pathways and Immune Function Of APCs Blood. 122: 1032-1032. DOI: 10.1182/Blood.V122.21.1032.1032 |
0.443 |
|
| 2013 |
Woods DM, Woan K, Cheng F, Wang HW, Sahakian E, Powers J, Rock-Klotz J, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation. Cancer Research. 73: 692-692. DOI: 10.1158/1538-7445.Am2013-692 |
0.459 |
|
| 2013 |
Tao J, Lwin T, Zhao X, Shah B, Zhang L, Moscinski L, Dalton W, Sotomayor EM, Tao J. Abstract 4944: Combined treatment of BTK and PI3K inhibitors synergistically disrupts BCR-signaling, overcomes microenviroment-mediated survival and drug resistance in mantle cell lymphoma. Cancer Research. 73: 4944-4944. DOI: 10.1158/1538-7445.Am2013-4944 |
0.449 |
|
| 2013 |
Horna P, Deaver DM, Moscinski LC, Sotomayor EM, Glass F, Sokol L. Quantitative Flow Cytometric Analysis in Erythrodermic Cutaneous T-Cell Lymphoma: Implications for Prognosis and Staging American Journal of Clinical Pathology. 140: A216-A216. DOI: 10.1093/Ajcp/140.Suppl1.216 |
0.341 |
|
| 2012 |
Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. Journal of Medicinal Chemistry. 55: 9891-9. PMID 23009203 DOI: 10.1021/Jm301098E |
0.339 |
|
| 2012 |
Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6227-38. PMID 22932665 DOI: 10.1158/1078-0432.Ccr-12-0873 |
0.397 |
|
| 2012 |
Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619 |
0.482 |
|
| 2012 |
Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control : Journal of the Moffitt Cancer Center. 19: 227-35. PMID 22710898 DOI: 10.1177/107327481201900307 |
0.357 |
|
| 2012 |
Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 120: 1027-38. PMID 22692508 DOI: 10.1182/Blood-2011-11-394346 |
0.372 |
|
| 2012 |
Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunology and Cell Biology. 90: 55-65. PMID 22105512 DOI: 10.1038/Icb.2011.96 |
0.404 |
|
| 2012 |
Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 31: 3002-8. PMID 22002311 DOI: 10.1038/Onc.2011.470 |
0.304 |
|
| 2012 |
Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunology, Immunotherapy : Cii. 61: 523-33. PMID 21983879 DOI: 10.1007/S00262-011-1109-0 |
0.444 |
|
| 2012 |
Jaglal M, Peker D, Bello CM, Shah BD, Sokol L, Zhang L, Sotomayor EM, Tao J, Cultrera JL. A review of clinicopathologic characteristics, therapy, and outcomes of 22 patients with aggressive B-cell lymphoma. Journal of Clinical Oncology. 30: e21123-e21123. DOI: 10.1200/Jco.2012.30.15_Suppl.E21123 |
0.358 |
|
| 2012 |
Freyer C, George T, Price S, Shah BD, Bello CM, Sokol L, Sotomayor EM, Cultrera JL. R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology. 30: e18509-e18509. DOI: 10.1200/Jco.2012.30.15_Suppl.E18509 |
0.341 |
|
| 2012 |
Kubal TE, Peker D, Sagatys E, Zhang L, Naghashpour M, Moscinski L, Sotomayor EM, Sokol L, Bello CM, Cultrera JL, Chervenick PA, Shah BD. Natural history and clinical prognosis of in situ mantle cell lymphoma. Journal of Clinical Oncology. 30: e18506-e18506. DOI: 10.1200/Jco.2012.30.15_Suppl.E18506 |
0.36 |
|
| 2012 |
Peker D, Kubal TE, Sotomayor EM, Sokol L, Cultrera JL, Bello CM, Chervenick PA, Sagatys E, Naghashpour M, Zhang L, Moscinski L, Shah BD. Unusual primary presentations of mantle cell lymphoma in the urinary tract and testes. Journal of Clinical Oncology. 30: e18503-e18503. DOI: 10.1200/Jco.2012.30.15_Suppl.E18503 |
0.376 |
|
| 2012 |
Crescentini RM, Sweet KL, Liu J, Liboy I, Dalia S, Chavez JC, Bello CM, Sokol L, Sotomayor EM, Cabanillas F, Cultrera JL. An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas. Journal of Clinical Oncology. 30: 8084-8084. DOI: 10.1200/Jco.2012.30.15_Suppl.8084 |
0.387 |
|
| 2012 |
Chavez JC, Domingo G, Dalia S, Dubovsky JA, Berchmans E, Powers JJ, Sweet KL, Crescentini RM, Sotomayor EM, Komrokji RS, Pinilla-Ibarz J. Cancer testicular antigens as a prognostic markers of chronic lymphocytic leukemia. Journal of Clinical Oncology. 30: 6575-6575. DOI: 10.1200/Jco.2012.30.15_Suppl.6575 |
0.358 |
|
| 2012 |
Dalia S, Chavez JC, Domingo G, Carballido EM, Aguayo-Hiraldo PI, Sweet KL, Crescentini RM, Sokol L, Bello CM, Cultrera JL, Shah BD, Lancet JE, Komrokji RS, Sotomayor EM, Pinilla-Ibarz J. Incidence of second and secondary malignancies in patients with CLL: A single institution experience. Journal of Clinical Oncology. 30: 6568-6568. DOI: 10.1200/Jco.2012.30.15_Suppl.6568 |
0.329 |
|
| 2012 |
Hasija N, Jaglal M, Duong V, Bello CM, Tomblyn MB, Forsyth PAJ, Sotomayor EM, Pan E, Sokol L. Primary CNS lymphoma: A review of clinicopathologic characteristics, therapy, and outcomes of 54 patients with primary CNS DLBCL. Journal of Clinical Oncology. 30: 2099-2099. DOI: 10.1200/Jco.2012.30.15_Suppl.2099 |
0.337 |
|
| 2012 |
Woods DM, Woan KV, Sahakian E, Powers J, Cheng F, Wang H, Rock-Klotz J, Weber JS, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype Blood. 120: 840-840. DOI: 10.1182/Blood.V120.21.840.840 |
0.484 |
|
| 2012 |
Cheng F, Wang Z, Wang H, Lienlaf M, Woan KV, Perez-Villarroel P, Rock-Klotz J, Sahakian E, Knox T, Woods DM, Powers J, Han R, Merino O, Deng S, Marante D, ... ... Sotomayor EM, et al. Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs) Blood. 120: 829-829. DOI: 10.1182/Blood.V120.21.829.829 |
0.494 |
|
| 2012 |
Lwin T, Zhao X, Cheng F, Zhang X, Zhang Y, Huang A, Moscinski L, Dalton WS, Sotomayor EM, Tao J. Targeting Mir-548m-HDAC6 Axis Circumvents Stroma- Mediated Drug Resistance (CAM-DR) and Clonogenicity in Non-Hodgkin B-Cell Lymphomas Blood. 120: 5094-5094. DOI: 10.1182/Blood.V120.21.5094.5094 |
0.401 |
|
| 2012 |
Shah BD, Martin P, Cultrera JL, Bello CM, Sokol L, Sotomayor EM. Time to Treatment of Greater Than 1 Year Optimally Stratifies Patients with Improved Survival in Mantle Cell Lymphoma Blood. 120: 5082-5082. DOI: 10.1182/Blood.V120.21.5082.5082 |
0.338 |
|
| 2012 |
Tao J, Lwin T, Zhao X, Zhang L, Moscinski L, Sotomayor EM, Dalton WS, Tao J. B Cell Receptor (BCR) Signal Pathways Confer Microenvironment-Mediated Drug Resistance and Are Promising Therapeutic Targets for B Cell Lymphomas Blood. 120: 4918-4918. DOI: 10.1182/Blood.V120.21.4918.4918 |
0.403 |
|
| 2012 |
Jaglal MV, Shah BD, Cultrera JL, Sotomayor EM, Tomblyn MB, Bello CM, Sokol L. Primary CNS Lymphoma in a HIV Negative Population: A Review of Clinicopathologic Characteristics, Therapy, and Outcomes of 59 Patients Blood. 120: 4858-4858. DOI: 10.1182/Blood.V120.21.4858.4858 |
0.35 |
|
| 2012 |
Li X, Xia B, Guo S, Sotomayor EM, Yu Y, Yang H, Zhao H, Zhao Z, Wang X, Wang Y, Zhang Y. A Retrospective Analysis of Gastric Diffuse Large B-Cell Lymphoma with or without MALT Component Blood. 120: 4856-4856. DOI: 10.1182/Blood.V120.21.4856.4856 |
0.326 |
|
| 2012 |
Sahakian E, Powers J, Horna P, Rock-Klotz J, Deng S, Woods DM, Nguyen M, Woan KV, Cheng F, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis Blood. 120: 4728-4728. DOI: 10.1182/Blood.V120.21.4728.4728 |
0.428 |
|
| 2012 |
Xia B, Li X, Zhang L, Guo Q, Jin X, Guo S, Sotomayor EM, Zhang Y. BTK inhibitor PCI-32765 targets endogenous and microenvironment-mediated B-cell receptor signaling to suppress lymphoma cell growth and is highly synergistic with Bortezmib against non-Hodgkin B-cell lymphomas Blood. 120: 4721-4721. DOI: 10.1182/Blood.V120.21.4721.4721 |
0.441 |
|
| 2012 |
Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Bradner JE, Dalton WS, Sotomayor EM, Tao J. Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas Blood. 120: 4618-4618. DOI: 10.1182/Blood.V120.21.4618.4618 |
0.354 |
|
| 2012 |
Shah BD, Little BJ, Cultrera J, Bello CM, Sokol L, Sotomayor EM, Tomblyn M, Ayala E. Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma Blood. 120: 4546-4546. DOI: 10.1182/Blood.V120.21.4546.4546 |
0.305 |
|
| 2012 |
Wang H, Cheng F, Wang Z, Lienlaf M, Perez-Villarroel P, Knox T, Sahakian E, Pinilla-Ibarz J, Horna P, Chen-Kiang S, Martin P, Bergman J, Kozikowski A, Villagra A, Tao J, ... ... Sotomayor EM, et al. Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL) Blood. 120: 3724-3724. DOI: 10.1182/Blood.V120.21.3724.3724 |
0.519 |
|
| 2012 |
Sahakian E, Rock-Klotz J, Shah BD, Powers J, Cultrera JL, Deng S, Woods DM, Nguyen M, Cheng F, Wang H, Perez-Villarroel P, Lienlaf M, Knox T, Chen-Kiang S, Villagra A, ... ... Sotomayor EM, et al. Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 120: 1660-1660. DOI: 10.1182/Blood.V120.21.1660.1660 |
0.445 |
|
| 2012 |
Lienlaf M, Perez-Villarroel P, Cheng F, Wang H, Marante D, Yoder S, V. WK, Knox T, Lagor S, Pinilla-Ibarz J, Seto E, Sotomayor EM, Villagra A. Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages Blood. 120: 1039-1039. DOI: 10.1182/Blood.V120.21.1039.1039 |
0.437 |
|
| 2012 |
Sahakian E, Powers J, Rock-Klotz J, Marsilio A, Woan K, Merino O, Gill A, Deng S, Cheng F, Villagra A, Luekette N, Seto E, Borrello I, Sotomayor E, Pinilla JI. Abstract 4260: Histone deacetylase 11 (HDAC11) as a novel therapeutic target in the regulation of myeloid-derived suppressor cell (MDSC) Cancer Research. 72: 4260-4260. DOI: 10.1158/1538-7445.Am2012-4260 |
0.443 |
|
| 2012 |
Woan KV, Vazquez L, Rock-Klotz J, Wang Z, Cheng F, Wang H, Woods D, Sahakian E, Perez P, Lienlaf M, Achille A, Bergman J, Kalin J, Gill A, Powers J, ... ... Sotomayor EM, et al. Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma Cancer Research. 72: 3555-3555. DOI: 10.1158/1538-7445.Am2012-3555 |
0.474 |
|
| 2012 |
Woods DM, Woan KV, Wang H, Cheng F, Wang Z, Vazquez L, Perez P, Lienlaf M, Rock-Klotz J, Sahakian E, Powers J, Deng S, Oscar M, Atadja P, Seto E, ... ... Sotomayor EM, et al. Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progressionin vivo Cancer Research. 72: 3554-3554. DOI: 10.1158/1538-7445.Am2012-3554 |
0.479 |
|
| 2011 |
Castillo JJ, Beltran BE, Morales D, Quinones P, Miranda R, Gallo A, Lopez-Ilasaca M, Desposorio CR, Hurtado de Mendoza F, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly in Peru: Report of 33 cases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18538. PMID 28023289 DOI: 10.1200/Jco.2011.29.15_Suppl.E18538 |
0.349 |
|
| 2011 |
Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. American Journal of Hematology. 86: 663-7. PMID 21761432 DOI: 10.1002/Ajh.22078 |
0.373 |
|
| 2011 |
Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leukemia Research. 35: 1571-7. PMID 21752466 DOI: 10.1016/J.Leukres.2011.06.023 |
0.315 |
|
| 2011 |
Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clinical Lymphoma, Myeloma & Leukemia. 11: 257-60. PMID 21658652 DOI: 10.1016/J.Clml.2011.03.012 |
0.308 |
|
| 2011 |
Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2787-94. PMID 21632504 DOI: 10.1200/Jco.2010.33.3005 |
0.322 |
|
| 2011 |
Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leukemia Research. 35: 1193-9. PMID 21377729 DOI: 10.1016/J.Leukres.2011.02.007 |
0.449 |
|
| 2011 |
Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. Journal of Immunology (Baltimore, Md. : 1950). 186: 3986-96. PMID 21368229 DOI: 10.4049/Jimmunol.1001101 |
0.804 |
|
| 2011 |
Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma. 52: 668-79. PMID 21271862 DOI: 10.3109/10428194.2010.550074 |
0.419 |
|
| 2011 |
Beltran BE, Castillo JJ, Salas R, Quiñones P, Morales D, Cotrina E, Miranda RN, Sotomayor EM. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leukemia & Lymphoma. 52: 153-6. PMID 21219127 DOI: 10.3109/10428194.2010.528094 |
0.376 |
|
| 2011 |
Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leukemia Research. 35: 394-404. PMID 20863567 DOI: 10.1182/Blood.V114.22.5116.5116 |
0.499 |
|
| 2011 |
Wang H, Wang Z, Cheng F, Woan KV, Rock-Klotz J, Sahakian E, Powers J, Javier P, Bergman J, Villagra A, Kozikowski A, Sotomayor EM. Tubastatin A, a Selective HDAC6 Inhibitor, Enhances Antigen-Presenting Cell (APC) Function and Restores the Responsiveness of Anergic CD4+ T Cells Blood. 118: 520-520. DOI: 10.1182/Blood.V118.21.520.520 |
0.503 |
|
| 2011 |
Cheng F, Wang Z, Wang H, Woan KV, Sahakian E, Klotz JR, Wang L, Han R, Merino O, Deng S, Vazquez L, Gill AS, Marante D, Powers J, Hancock WW, ... ... Sotomayor EM, et al. Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs) Blood. 118: 519-519. DOI: 10.1182/Blood.V118.21.519.519 |
0.427 |
|
| 2011 |
Patel JR, Ho VQ, Teichman ML, Sokol L, Bello CM, Cultrera JL, Sotomayor EM, Wetzstein GA. Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible? Blood. 118: 4973-4973. DOI: 10.1182/Blood.V118.21.4973.4973 |
0.308 |
|
| 2011 |
Chavez JC, Zhang L, Sagatys EM, Sokol L, Moscinski L, Sotomayor EM, Shah BD. Lymphomatoid Granulomatosis: A Clinicopathologic Study of a Series of Cases in a Single Institution Blood. 118: 4960-4960. DOI: 10.1182/Blood.V118.21.4960.4960 |
0.312 |
|
| 2011 |
Deaver D, Zuckerman KS, Bello CM, Sotomayor EM, Bruno S, Sokol L. Primary and Secondary Ocular Adnexal Lymphoma: A Single Institutional Experience Blood. 118: 4956-4956. DOI: 10.1182/Blood.V118.21.4956.4956 |
0.371 |
|
| 2011 |
Pound HB, Ho VQ, Bello CM, Cultrera JL, Extermann M, Lancet JE, Sotomayor EM, Pinilla-Ibarz J. Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience Blood. 118: 4620-4620. DOI: 10.1182/Blood.V118.21.4620.4620 |
0.311 |
|
| 2011 |
Shah BD, Tao J, Sokol L, Chervenick PA, Tomblyn M, Pinilla-Ibarz J, Moscinski L, Antonia S, Sotomayor EM, Dessureault S. Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL), Blood. 118: 3720-3720. DOI: 10.1182/Blood.V118.21.3720.3720 |
0.365 |
|
| 2011 |
Woan KV, Wang D, Wang Z, Cheng F, Vazquez L, Woods D, Yu Y, Sahakian E, Wang H, Telles E, Peng L, Wang L, Hancock WW, Blazar BR, Luetteke N, ... ... Sotomayor EM, et al. Histone Deacetylase 11 (HDAC11) Is a Regulatory Checkpoint of T-Cell Function: Implications for T-Cell Adoptive Immunotherapy Blood. 118: 359-359. DOI: 10.1182/Blood.V118.21.359.359 |
0.478 |
|
| 2011 |
Kharfan-Dabaja MA, Anasetti C, Luis N, Brand L, Perkins J, Fernandez HF, Ochoa-Bayona JL, Nishihori T, Perez LE, Ayala E, Pinilla-Ibarz J, Sokol L, Pidala J, Locke FL, Sotomayor EM, et al. Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression Blood. 118: 3022-3022. DOI: 10.1182/Blood.V118.21.3022.3022 |
0.327 |
|
| 2011 |
Sahakian E, Powers J, Rock-Klotz J, Adriani M, Woan KV, Merino O, Gill AS, Deng S, Cheng F, Villagra A, Luetteke N, Seto E, Sotomayor EM, Borrello IM, Pinilla-Ibarz J. A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion Blood. 118: 2439-2439. DOI: 10.1182/Blood.V118.21.2439.2439 |
0.43 |
|
| 2011 |
Fiskus W, Sharma S, Rao R, Balusu R, Venkannagari S, Hembruff S, Ganguly S, Sotomayor EM, Tao J, Bearss DJ, Bhalla KN. Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells Blood. 118: 2429-2429. DOI: 10.1182/Blood.V118.21.2429.2429 |
0.411 |
|
| 2011 |
Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725 |
0.352 |
|
| 2011 |
Sahakian E, Shah BD, Powers J, Deng S, Merino O, Gill AS, Rock-Klotz J, Woan KV, Vazquez L, Wang H, Chen-Kiang S, Tao J, Villagra A, Pinilla-Ibarz J, Sotomayor EM. The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) Blood. 118: 1363-1363. DOI: 10.1182/Blood.V118.21.1363.1363 |
0.472 |
|
| 2011 |
Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2’-deoxycytidine Cancer Research. 71: 5526-5526. DOI: 10.1158/1538-7445.Am2011-5526 |
0.446 |
|
| 2011 |
Fiskus WC, Sharma S, Rao R, Balusu R, Tao J, Sotomayor E, Atadja P, Ganguly S, Bearss D, Bhalla KN. Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells Cancer Research. 71: 2016-2016. DOI: 10.1158/1538-7445.Am2011-2016 |
0.402 |
|
| 2010 |
Sotomayor EM. "Skulls and bones" new member: Th17. Blood. 116: 3380-2. PMID 21051562 DOI: 10.1182/Blood-2010-08-300574 |
0.35 |
|
| 2010 |
Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 116: 5228-36. PMID 20841506 DOI: 10.1182/Blood-2010-03-275925 |
0.38 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4742-54. PMID 20647473 DOI: 10.1158/1078-0432.Ccr-10-0529 |
0.398 |
|
| 2010 |
Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Molecular Cancer Research : McR. 8: 907-18. PMID 20530581 DOI: 10.1158/1541-7786.Mcr-10-0131 |
0.462 |
|
| 2010 |
Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, Chen J, Lane WS, Seto E. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Molecular and Cellular Biology. 30: 3004-15. PMID 20368352 DOI: 10.1128/Mcb.01023-09 |
0.311 |
|
| 2010 |
Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunology Letters. 131: 126-30. PMID 20346983 DOI: 10.1016/J.Imlet.2010.03.004 |
0.797 |
|
| 2010 |
Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Current Pharmaceutical Design. 16: 268-76. PMID 20109136 DOI: 10.2174/138161210790170120 |
0.377 |
|
| 2010 |
Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: Implications in cancer and inflammation Oncogene. 29: 157-173. PMID 19855430 DOI: 10.1038/Onc.2009.334 |
0.371 |
|
| 2010 |
Shah BD, Tao J, Sokol L, Chervenick PA, Tomblyn MR, Pinilla-Ibarz J, Moscinski L, Antonia S, Sotomayor EM, Dessureault S. Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results. Journal of Clinical Oncology. 28: 2608-2608. DOI: 10.1200/Jco.2010.28.15_Suppl.2608 |
0.385 |
|
| 2010 |
Woan K, Cheng F, Wang H, Rock-Klotz J, Wang Z, Yu Y, Seto E, Luetteke N, Yu X, Villagra A, Sotomayor EM. Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 with a TH17 Phenotype Blood. 116: 588-588. DOI: 10.1182/Blood.V116.21.588.588 |
0.472 |
|
| 2010 |
Shah BD, Cultrera JL, Sokol L, Chervenick PA, Bello CM, Sagatys EM, Moscinski LC, Zhang L, Tao J, Sotomayor EM. Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) as An Indicator of Overall Survival, Progression Free Survival, Survival From Relapse Blood. 116: 5082-5082. DOI: 10.1182/Blood.V116.21.5082.5082 |
0.331 |
|
| 2010 |
Dubovsky JA, Powers J, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz J. Molecular, Epigenetic, and Phenotypic Repolarization of T Lymphocytes From Chronic Lymphocytic Leukemia Patients Using 5-Aza-2′-Deoxycytidine Blood. 116: 4651-4651. DOI: 10.1182/Blood.V116.21.4651.4651 |
0.433 |
|
| 2010 |
Veliz M, Powers J, Zhang L, Santana E, Lancet JE, Komrokji RS, Kharfan-Dabaja M, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J. Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL Blood. 116: 4630-4630. DOI: 10.1182/Blood.V116.21.4630.4630 |
0.43 |
|
| 2010 |
Beltran B, Morales D, Quinones P, Gallo A, Lopez-Ilasaca M, Miranda R, Sotomayor EM, Castillo JJ. Prevalence and Prognostic Factors of EBV-Positive DLBCL of the Elderly In Peru Blood. 116: 4166-4166. DOI: 10.1182/Blood.V116.21.4166.4166 |
0.362 |
|
| 2010 |
Liu J, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Sotomayor EM, Sokol L. Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases Blood. 116: 4162-4162. DOI: 10.1182/Blood.V116.21.4162.4162 |
0.35 |
|
| 2010 |
Lin J, Lwin T, Tam W, Zhao J, Crespo L, Choi YS, Zhang X, Tannenbaum V, Sotomayor EM, Moscinski LC, Dalton WS, Wright K, Tao J. Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis. Blood. 116: 3853-3853. DOI: 10.1182/Blood.V116.21.3853.3853 |
0.333 |
|
| 2010 |
Zhang X, Chen X, Lin J, Lwin T, Ely SA, Chen-Kiang S, Dalton WS, Seto E, Wright K, Sotomayor EM, Tao J. Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma Blood. 116: 3121-3121. DOI: 10.1182/Blood.V116.21.3121.3121 |
0.325 |
|
| 2010 |
Lwin T, Lin J, Choi YS, Zhang X, Moscinski L, Wright K, Sotomayor EM, Dalton W, Tao J. Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas Blood. 116: 3118-3118. DOI: 10.1182/Blood.V116.21.3118.3118 |
0.384 |
|
| 2010 |
Beltran B, Salas R, Chunga A, Sotomayor EM, Castillo JJ. Quantification of EBV DNA In Whole Blood In Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Blood. 116: 3102-3102. DOI: 10.1182/Blood.V116.21.3102.3102 |
0.344 |
|
| 2010 |
Padron E, Komrokji RS, Lancet JE, List AF, Dessureault S, Antonia S, Ahmed J, Patel S, Powers J, Bai F, Sotomayor EM, Epling-Burnette P, Pinilla-Ibarz J. A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS) Blood. 116: 2925-2925. DOI: 10.1182/Blood.V116.21.2925.2925 |
0.386 |
|
| 2010 |
Cultrera JL, Liu J, Liboy I, Bello CM, Sokol L, Sotomayor EM, Santana E, Cabanillas F. A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas Blood. 116: 2879-2879. DOI: 10.1182/Blood.V116.21.2879.2879 |
0.393 |
|
| 2010 |
Rao R, Fiskus W, Balusu R, Ma H, Bradner J, Tao J, Sotomayor EM, Bhalla KN. Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib Blood. 116: 2856-2856. DOI: 10.1182/Blood.V116.21.2856.2856 |
0.39 |
|
| 2010 |
Shah BD, Villagra A, Merino O, Rock-Klotz J, Woan K, Seto E, Martin P, Leonard JP, Chen-Kiang S, Tao J, Sotomayor EM. HDAC Profiling In Mantle Cell Lymphoma Unveils HDAC11 and HDAC10 as Potential Molecular Targets Blood. 116: 2506-2506. DOI: 10.1182/Blood.V116.21.2506.2506 |
0.453 |
|
| 2010 |
Fiskus W, Rao R, Balusu R, Tao J, Sotomayor EM, Atadja P, Bhalla KN. Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells Blood. 116: 2488-2488. DOI: 10.1182/Blood.V116.21.2488.2488 |
0.389 |
|
| 2010 |
Cheng F, Wang H, Woan K, Rock-Klotz J, Wang Z, Merino O, Gill A, Marante D, Vazquez L, Seto E, Pinilla-Ibarz J, Sotomayor EM, Villagra A. Targeting Histone Deacetylase 6 (HDAC6) as a Novel Approach to Overcome T-Cell Anergy. Blood. 116: 1483-1483. DOI: 10.1182/Blood.V116.21.1483.1483 |
0.469 |
|
| 2010 |
Wang D, Cheng F, Yu Y, Semple K, Peng L, Telles E, Luetteke N, Seto E, Anasetti C, Sotomayor EM, Yu X. HDAC11 Inhibits T-Cell Response to Alloantigens and Reduces Gvhd In Mice. Blood. 116: 1466-1466. DOI: 10.1182/Blood.V116.21.1466.1466 |
0.461 |
|
| 2010 |
Dubovsky JA, Powers JJ, Gao Y, Pinilla-Ibarz JA, Sotomayor EM. Abstract 4771: Molecular, epigenetic, and phenotypic repolarization of human T lymphocytes using 5-aza-2′-deoxycytidine increases CD8 responsiveness and induces Th1 polarity Cancer Research. 70: 4771-4771. DOI: 10.1158/1538-7445.Am10-4771 |
0.431 |
|
| 2009 |
Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, Winter JN, Flowers CR, Stergiou AM, Kwak LW. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2. PMID 27937596 DOI: 10.1200/Jco.2009.27.15_Suppl.2 |
0.333 |
|
| 2009 |
Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunology Letters. 125: 114-8. PMID 19555720 DOI: 10.1016/J.Imlet.2009.06.007 |
0.791 |
|
| 2009 |
Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biology & Therapy. 8: 1273-80. PMID 19440035 DOI: 10.4161/Cbt.8.13.8726 |
0.374 |
|
| 2009 |
Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3406-15. PMID 19401350 DOI: 10.1182/Blood.V112.11.4207.4207 |
0.41 |
|
| 2009 |
Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 182: 5693-701. PMID 19380816 DOI: 10.4049/Jimmunol.0900092 |
0.425 |
|
| 2009 |
Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology. 10: 92-100. PMID 19011628 DOI: 10.1038/Ni.1673 |
0.486 |
|
| 2009 |
Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 23: 170-7. PMID 18843286 DOI: 10.1038/Leu.2008.266 |
0.431 |
|
| 2009 |
Shah BD, Sagatys E, Zhang L, Moscinski LC, Sotomayor EM. Brisk Lymphocytosis with Aberrant Expression of CD5 in the Leukemic Phase of Follicular Lymphoma. Blood. 114: 5033-5033. DOI: 10.1182/Blood.V114.22.5033.5033 |
0.391 |
|
| 2009 |
Beltran B, Quinones P, Morales D, Capellino A, Miranda R, Bueso-Ramos CE, Sotomayor EM, Castillo J. Clinical Outcome and Survival of EBV-Positive Diffuse Large B-Cell Lymphoma. Blood. 114: 5005-5005. DOI: 10.1182/Blood.V114.22.5005.5005 |
0.362 |
|
| 2009 |
Dubovsky JA, Berchmans E, Powers JJ, Hui-Yi L, Gao Y, Sotomayor E, Pinilla J. Molecular Profiling of Cancer Testis Antigens in Chronic Lymphocytic Leukemia. Blood. 114: 4701-4701. DOI: 10.1182/Blood.V114.22.4701.4701 |
0.368 |
|
| 2009 |
Lin J, Lwin T, Zhao J, Zhao J, Crespo L, Sotomayor EM, Moscinski LC, Dalton WS, Wright K, Tao J. Follicular Dendritic Cell (FDC)-Induced Microrna-Mediated up-Regulation of PRDM1 and Down-Regulation of BCL6 in Germinal Center B Lymphocytes: A Potential Mechanism for B-Cell Differentiation. Blood. 114: 4588-4588. DOI: 10.1182/Blood.V114.22.4588.4588 |
0.402 |
|
| 2009 |
Shah BD, Veliz M, Santana R, Lancet JE, Powers JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla J. Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL). Blood. 114: 4413-4413. DOI: 10.1182/Blood.V114.22.4413.4413 |
0.335 |
|
| 2009 |
Veliz M, Moscinski LC, Zhang L, Sotomayor EM, Pinilla-Ibarz J. Lymphoplasmacytic Differentiation Associated with Lenalidomide Therapy in Patients with Chronic Lymphocytic Leukemia. Blood. 114: 4412-4412. DOI: 10.1182/Blood.V114.22.4412.4412 |
0.429 |
|
| 2009 |
Veliz M, Santana R, Lancet JE, Komrokji RS, Kharfan-Dabaja MA, Powers JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J. Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis. Blood. 114: 2376-2376. DOI: 10.1182/Blood.V114.22.2376.2376 |
0.374 |
|
| 2009 |
Powers JJ, Dubovsky JA, Zhang L, Moscinski LC, Epling-Burnette P, Sotomayor EM, Pinilla J. Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy. Blood. 114: 2204-2204. DOI: 10.1182/Blood.V114.22.2204.2204 |
0.434 |
|
| 2009 |
Lin J, Zhao J, Lwin T, Luis C, Guan F, Dessureault S, Moscinski LC, Dalton WS, Sotomayor EM, Cheng J, Tao J. MiR-29 MicroRNAs Regulate IGF-1R Expression and Contribute Mantle Cell Lymphoma Growth and Survival. Blood. 114: 1957-1957. DOI: 10.1182/Blood.V114.22.1957.1957 |
0.314 |
|
| 2009 |
Beltran B, Morales D, Quinones P, Desposorio C, Sotomayor E, Castillo J. Lymphopenia Predicts Survival in Peripheral T-Cell Lymphoma, Unspecified. Blood. 114: 1930-1930. DOI: 10.1182/Blood.V114.22.1930.1930 |
0.377 |
|
| 2009 |
Cheng F, Wang H, Luetteke N, Pinilla J, Kozikowski A, Seto E, Villagra Av, Sotomayor E. A Novel Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-10 and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood. 114: 1360-1360. DOI: 10.1182/Blood.V114.22.1360.1360 |
0.474 |
|
| 2009 |
Villagra A, Cheng F, Wang H, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. Erratum: The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance Nature Immunology. 10: 665-665. DOI: 10.1038/Ni0609-665C |
0.335 |
|
| 2008 |
Wang H, Cheng F, Wright K, Tao J, Smith M, Pinilla J, Dessureault S, Sebti S, Sotomayor E. Targeting STAT3 Signaling to Augment the Immunogenicity of B-Cell Lymphomas Blood. 112: 708-708. DOI: 10.1182/blood.v112.11.708.708 |
0.423 |
|
| 2008 |
Villagra Av, Maurin Mm, Cheng F, Wang H, Dessureault S, Seto E, Tao J, Wright K, Pinilla J, Sotomayor EM. Histone Deacetylase 11 (HDAC11) as a Novel Molecular Target in Mantle Cell Lymphoma Blood. 112: 4494-4494. DOI: 10.1182/Blood.V112.11.4494.4494 |
0.471 |
|
| 2008 |
Kharfan-Dabaja MA, Tate C, Perkins J, Field T, Fernandez HF, Alsina M, Ayala E, Raychaudhuri J, Perez L, Ochoa-Bayona JL, Brand L, Pinilla-Ibarz J, Sotomayor E, Sullivan D, Anasetti C. Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies Blood. 112: 4323-4323. DOI: 10.1182/Blood.V112.11.4323.4323 |
0.313 |
|
| 2008 |
Dubovsky JA, Powers JJ, Sotomayor EM, Pinilla J. Changes in Immunogenicity of Chronic Lymphocytic Leukemia Cells Mediated by Epigenetic Modifiers Blood. 112: 4202-4202. DOI: 10.1182/Blood.V112.11.4202.4202 |
0.437 |
|
| 2008 |
Fiskus W, Wang Y, Jillella A, Johnston P, Joshi R, Rao R, Sotomayor E, Tao J, Atadja P, Marqez V, Bhalla KN. Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells Blood. 112: 3622-3622. DOI: 10.1182/Blood.V112.11.3622.3622 |
0.404 |
|
| 2008 |
Vicente-Suarez I, Villagra A, Sotomayor EM. Signaling pathways in antigen-presenting cells involved in the induction of antigen-specific T-cell tolerance Tumor Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 197-218. DOI: 10.1007/978-0-387-69118-3_9 |
0.785 |
|
| 2007 |
Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 233-42. PMID 18024635 DOI: 10.1182/Asheducation-2007.1.233 |
0.352 |
|
| 2007 |
Vicente-Suarez I, Takahashi Y, Cheng F, Horna P, Wang HW, Wang HG, Sotomayor EM. Identification of a novel negative role of flagellin in regulating IL-10 production. European Journal of Immunology. 37: 3164-75. PMID 17948265 DOI: 10.1002/Eji.200737306 |
0.77 |
|
| 2007 |
Villagra A, Ulloa N, Zhang X, Yuan Z, Sotomayor E, Seto E. Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression Journal of Biological Chemistry. 282: 35457-35470. PMID 17925399 DOI: 10.1074/Jbc.M701719200 |
0.322 |
|
| 2007 |
Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 110: 1631-8. PMID 17502456 DOI: 10.1182/Blood-2006-11-060350 |
0.416 |
|
| 2007 |
Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21: 1521-31. PMID 17476277 DOI: 10.1038/Sj.Leu.2404723 |
0.405 |
|
| 2007 |
Horna P, Sotomayor EM. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Current Cancer Drug Targets. 7: 41-53. PMID 17305477 DOI: 10.2174/156800907780006940 |
0.451 |
|
| 2007 |
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology. 25: 267-96. PMID 17134371 DOI: 10.1146/Annurev.Immunol.25.022106.141609 |
0.403 |
|
| 2007 |
Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Annals of Surgical Oncology. 14: 869-84. PMID 17103257 DOI: 10.1245/S10434-006-9196-4 |
0.406 |
|
| 2007 |
Dessureault S, Noyes D, Tao J, Moscinski L, Schell M, Antonia SJ, Sotomayor EM. Bystander-Based Immunotherapy for Patients with Mantle Cell Lymphoma (MCL): Proof of Principle. Blood. 110: 4483-4483. DOI: 10.1182/Blood.V110.11.4483.4483 |
0.369 |
|
| 2007 |
Cheng F, Horna P, Wang H, Suarez I, Chen X, Wei S, Sotomayor EM. Critical Role of Neutrophils in Determining Antigen-Specific CD4+ T-Cell Tolerance In Vivo. Blood. 110: 3294-3294. DOI: 10.1182/Blood.V110.11.3294.3294 |
0.444 |
|
| 2007 |
Wang H, Cheng F, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM, Sotomayor IbEM. Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies. Blood. 110: 2315-2315. DOI: 10.1182/Blood.V110.11.2315.2315 |
0.522 |
|
| 2007 |
Vicente-Suarez I, Sotomayor EM. Ligation of TLR5 by Flagellin Converts Tolerogenic Dendritic Cells into Activating Dendritic Cells through Inhibition of IL-10 Production. Blood. 110: 2314-2314. DOI: 10.1182/Blood.V110.11.2314.2314 |
0.783 |
|
| 2007 |
Sagatys E, Moscinski L, Dessureault S, Sotomayor E, Cualing H. Analysis of T-Cell Subpopulations in the Lymph Nodes of Patients with Mantle Cell Lymphoma. Blood. 110: 1580-1580. DOI: 10.1182/Blood.V110.11.1580.1580 |
0.339 |
|
| 2007 |
Mohapatra S, Chu B, Zhao X, Tao J, Sotomayor E, Pledger WJ. Combined Inhibition of CDK and PI3K/Akt Pathways Induces Apoptosis of Mantle Cell Lymphoma. Blood. 110: 1384-1384. DOI: 10.1182/Blood.V110.11.1384.1384 |
0.404 |
|
| 2007 |
Rao R, Fiskus W, Joshi R, Chen J, Fernandez P, Wang Y, Lee P, Jillella A, Tao J, Atadja P, Sotomayor E, Bhalla K. Targeting Histone Deacetylases and Unfolded Protein Mediated Endoplasmic Reticulum (ER) Stress as a Strategy Against Human Mantle Cell Lymphoma. Blood. 110: 1378-1378. DOI: 10.1182/Blood.V110.11.1378.1378 |
0.379 |
|
| 2007 |
Wang H, Cheng F, Nguyen D, Suarez I, Wright K, Atadja A, Seto E, Bhalla K, Villagra A, Sotomayor E. A Novel Role of Histone Deacetylase 11 (HDAC11) in the Regulation of IL-10 Production and Immune Tolerance Mediated by Antigen-Presenting Cells. Blood. 110: 1330-1330. DOI: 10.1182/Blood.V110.11.1330.1330 |
0.459 |
|
| 2006 |
Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 107: 2871-8. PMID 16339406 DOI: 10.1182/Blood-2005-07-3014 |
0.458 |
|
| 2005 |
Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 105: 1135-43. PMID 15454486 DOI: 10.1182/Blood-2004-01-0027 |
0.457 |
|
| 2005 |
Horna P, Chavan R, Brayer J, Suarez I, Sotomayor EM. Age-Related Induction of CD4+ T-Cell Unresponsiveness Is Reversible and Dependant of the Host’s Environment. Blood. 106: 3925-3925. DOI: 10.1182/Blood.V106.11.3925.3925 |
0.448 |
|
| 2005 |
Hatter A, Bali P, Balasis M, Fiskus W, Boyapalle S, Kumaraswamy S, Rocha K, Pranpat M, Hannah A, Sotomayor E, Richon V, Bhalla K. Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells. Blood. 106: 2418-2418. DOI: 10.1182/Blood.V106.11.2418.2418 |
0.366 |
|
| 2005 |
Wang H, Cheng F, Horna P, Suarez I, Wu J, Atadja A, Seto E, Wright K, Bhalla K, Sotomayor E. Treatment of Antigen-Presenting Cells with Histone Deacetylase Inhibitors Represents a Novel Strategy To Overcome CD4+ T-Cell Tolerance: Divergent Effects on the IL10 and IL-12 Promoter. Blood. 106: 2392-2392. DOI: 10.1182/Blood.V106.11.2392.2392 |
0.418 |
|
| 2005 |
Wang H, Naing A, Cheng F, Horna P, Suarez I, Brayer J, List AF, Sotomayor EM. The Immunomodulatory Drug Lenalidomide (CC5013; Revlimid), Enhances Antigen-Presenting Cell’s Function Leading to Effective Priming of CD4+ T-Lymphocytes. Blood. 106: 2391-2391. DOI: 10.1182/Blood.V106.11.2391.2391 |
0.503 |
|
| 2005 |
Cheng F, Wang H, Suarez A, Horna P, Sebti S, Sotomayor EM. Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance. Blood. 106: 1485-1485. DOI: 10.1182/Blood.V106.11.1485.1485 |
0.506 |
|
| 2004 |
Cheng F, Gabrilovich D, Sotomayor EM. Immune tolerance in breast cancer. Breast Disease. 20: 93-103. PMID 15687711 DOI: 10.3233/Bd-2004-20111 |
0.336 |
|
| 2004 |
Ghansah T, Paraiso KH, Highfill S, Desponts C, May S, McIntosh JK, Wang JW, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr WG. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. Journal of Immunology (Baltimore, Md. : 1950). 173: 7324-30. PMID 15585856 DOI: 10.4049/Jimmunol.173.12.7324 |
0.434 |
|
| 2004 |
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Research. 64: 5839-49. PMID 15313928 DOI: 10.1158/0008-5472.Can-04-0465 |
0.438 |
|
| 2004 |
Brayer J, Cheng F, Horna P, Suarez I, Wang H, Sotomayor EM. Analysis of the Fate and Function of Antigen-Specific CD8 T Cells during B Cell Lymphoma Progression. Blood. 104: 80-80. DOI: 10.1182/Blood.V104.11.80.80 |
0.456 |
|
| 2004 |
Horna P, Cheng F, Jove R, Mora L, Sotomayor EM. In Vivo Visualization of Stat3 Activation in Myeloid Cells during Inflammation and Tumor Growth. Blood. 104: 3434-3434. DOI: 10.1182/Blood.V104.11.3434.3434 |
0.471 |
|
| 2004 |
Cheng F, Wang H, Cuenca AG, Horna P, Suarez L, Brayer J, Turkson J, Jove R, Sotomayor EM. Disruption of STAT3 Signaling in Antigen Presenting Cells Represents a Novel Strategy To Overcome Tumor-Induced Antigen-Specific CD4+ T-Cell Tolerance. Blood. 104: 109-109. DOI: 10.1182/Blood.V104.11.109.109 |
0.467 |
|
| 2003 |
Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM. A critical role for Stat3 signaling in immune tolerance. Immunity. 19: 425-36. PMID 14499117 DOI: 10.1016/S1074-7613(03)00232-2 |
0.451 |
|
| 2002 |
Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM. Advances in gene therapy for malignant melanoma. Cancer Control : Journal of the Moffitt Cancer Center. 9: 39-48. PMID 11907465 DOI: 10.1177/107327480200900106 |
0.302 |
|
| 2001 |
Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood. 98: 1070-1077. PMID 11493453 DOI: 10.1182/Blood.V98.4.1070 |
0.453 |
|
| 2001 |
Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells Journal of Immunology. 166: 5398-5406. PMID 11313376 DOI: 10.4049/Jimmunol.166.9.5398 |
0.47 |
|
| 2000 |
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)- producing tumor vaccines Blood. 95: 3011-3019. PMID 10807763 DOI: 10.1182/Blood.V95.10.3011.010K15_3011_3019 |
0.366 |
|
| 2000 |
Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. The Journal of Experimental Medicine. 191: 541-50. PMID 10662799 DOI: 10.1084/Jem.191.3.541 |
0.366 |
|
| 1999 |
Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Medicine. 5: 780-7. PMID 10395323 DOI: 10.1038/10503 |
0.432 |
|
| 1996 |
Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: A critical issue in tumor immunology Critical Reviews in Oncogenesis. 7: 433-456. PMID 9467666 DOI: 10.1615/Critrevoncog.V7.I5-6.30 |
0.41 |
|
| 1995 |
Sotomayor EM, DiNapoli MR, Calderon C, Colsky A, Fu YX, Lopez DM. Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release International Journal of Cancer. 60: 660-667. PMID 7860141 DOI: 10.1002/Ijc.2910600516 |
0.316 |
|
| 1994 |
César Calderón H, Huang ZH, Gage DA, Sotomayor EM, Lopez DM. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine Journal of Experimental Medicine. 180: 945-958. PMID 8064242 DOI: 10.1084/Jem.180.3.945 |
0.341 |
|
| Show low-probability matches. |